CERo Therapeutics Holdings, Inc. (CERO) 10-Year Financial Performance & Capital Metrics

CERO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutCERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.Show more

Revenue $0
EBITDA -$14M -382.5%
Net Income -$8M -304789.6%
EPS (Diluted) -6.87 +99.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 1 (bottom 1%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-124.48%

EPS CAGR

10Y-

5Y-

3Y-

TTM85.64%

ROCE

10Y Avg-17.97%

5Y Avg-17.97%

3Y Avg-26.86%

Latest-

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0
Revenue Growth %	-	-	-	-
Cost of Goods Sold+	0	0	1.12M	1.16M
COGS % of Revenue	-	-	-	-
Gross Profit+	0	0	-1.12M	-1.16M
Gross Margin %	-	-	-	-
Gross Profit Growth %	-	-	-	-0.04%
Operating Expenses+	431.5K	2.91M	2.93M	15.3M
OpEx % of Revenue	-	-	-	-
Selling, General & Admin	2.48M	2.84M	2.89M	8.98M
SG&A % of Revenue	-	-	-	-
Research & Development	9.14M	9.85M	0	6.32M
R&D % of Revenue	-	-	-	-
Other Operating Expenses	-11.18M	-9.78M	40.05K	351
Operating Income+	-332.03K	-2.91M	-2.93M	-15.3M
Operating Margin %	-	-	-	-
Operating Income Growth %	-	-7.75%	-0.01%	-4.22%
EBITDA+	403.44K	1	-2.93M	-14.14M
EBITDA Margin %	-	-	-	-
EBITDA Growth %	-	-1%	-999999%	-3.83%
D&A (Non-Cash Add-back)	735.47K	2.91M	2.93K	1.16M
EBIT	-332.42K	-2.91M	-2.44M	-7.73M
Net Interest Income+	986.71K	2.84M	138.34K	26.65K
Interest Income	986.71K	2.84M	138.34K	26.65K
Interest Expense	0	0	0	0
Other Income/Expense	-385	2.84M	491.57K	7.57M
Pretax Income+	-332.42K	-68.58K	-2.44M	-7.73M
Pretax Margin %	-	-	-	-
Income Tax+	-16.87K	599.16K	94.82K	0
Effective Tax Rate %	0.95%	9.74%	0%	1%
Net Income+	-315.55K	-667.74K	-2.54K	-7.73M
Net Margin %	-	-	-	-
Net Income Growth %	-	-1.12%	1%	-3047.9%
Net Income (Continuing)	-315.55K	-667.74K	-2.54M	-7.73M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-2.75	-19.73	-2497.20	-6.87
EPS Growth %	-	-6.17%	-125.57%	1%
EPS (Basic)	-2.75	-19.73	-2497.20	-6.87
Diluted Shares Outstanding	114.9K	33.84K	2.92K	1.21M
Basic Shares Outstanding	114.9K	33.84K	2.92K	1.21M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.36M	42.37M	1.97M	3.71M
Cash & Short-Term Investments	1.1M	42.14M	1.6M	3.33M
Cash Only	1.1M	42.14M	1.6M	3.33M
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	0	0
Days Sales Outstanding	-	-	-	-
Inventory	0	0	0	0
Days Inventory Outstanding	-	-	-	-
Other Current Assets	262.5K	225.19K	341.35K	386.98K
Total Non-Current Assets+	178.72M	4.27M	3.16M	2.49M
Property, Plant & Equipment	4.65M	4.27M	3.16M	1.99M
Fixed Asset Turnover	-	-	-	-
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	178.5M	0	0	1.3M
Other Non-Current Assets	200.65K	0	0	-795.44K
Total Assets+	180.08M	42.37M	5.13M	6.21M
Asset Turnover	-	-	-	-
Asset Growth %	-	-0.76%	-0.88%	0.21%
Total Current Liabilities+	98.07K	30.75M	5.17M	7.4M
Accounts Payable	14.43K	1.65M	3.54M	4.51M
Days Payables Outstanding	-	-	1.15K	1.41K
Short-Term Debt	0	650K	1.55M	876.39K
Deferred Revenue (Current)	0	597.5K	0	0
Other Current Liabilities	-585.25K	27.77M	23.63K	264.3K
Current Ratio	13.88x	1.38x	0.38x	0.50x
Quick Ratio	13.88x	1.38x	0.38x	0.50x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	9.15M	9.15M	17.59M	699.11K
Long-Term Debt	0	0	0	0
Capital Lease Obligations	0	0	1.58M	699.11K
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	9.15M	9.15M	17.59M	0
Total Liabilities	9.25M	39.9M	47.18M	8.1M
Total Debt+	3.6M	650K	1.55M	1.58M
Net Debt	2.5M	-41.49M	1.46M	-1.75M
Debt / Equity	0.02x	0.26x	-	-
Debt / EBITDA	8.93x	650000.00x	-	-
Net Debt / EBITDA	6.21x	-999999.00x	-	-
Interest Coverage	-	-	-	-
Total Equity+	170.83M	2.47M	-5.76M	-1.89M
Equity Growth %	-	-0.99%	-3.33%	0.67%
Book Value per Share	1486.77	72.95	-1974.24	-1.57
Total Shareholders' Equity	170.83M	2.47M	-5.76M	-1.89M
Common Stock	178.5M	13.22M	0	242
Retained Earnings	-7.67M	-10.76M	-43.09M	-70.92M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	0
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-697.11K	-1.09M	-5.79M	-5.79M
Operating CF Margin %	-	-	-	-
Operating CF Growth %	-	-0.57%	-4.3%	0%
Net Income	-10.63M	-11.83M	-7.29M	-8.3M
Depreciation & Amortization	735.47K	1.07M	1.12M	1.12M
Stock-Based Compensation	287.74K	381.07K	96.9K	96.9K
Deferred Taxes	0	0	0	0
Other Non-Cash Items	9.27M	6.87M	-254.61K	-536.85K
Working Capital Changes	-365.08K	2.41M	540.11K	1.84M
Change in Receivables	0	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	0	0	1.28M	258.46K
Cash from Investing+	-178.5M	180.84M	-7.94K	0
Capital Expenditures	-612.57K	-694.23K	0	0
CapEx % of Revenue	-	-	-	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	-177.89M	181.86M	8.69M	0
Cash from Financing+	180.3M	-138.7M	571.68K	571.68K
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	0	-139.21M	0	-13.14M
Net Change in Cash	-	-	-	-
Free Cash Flow+	-1.31M	-1.79M	-5.79M	-5.79M
FCF Margin %	-	-	-	-
FCF Growth %	-	-0.36%	-2.24%	0%
FCF per Share	-11.40	-52.79	-1983.55	-4.79
FCF Conversion (FCF/Net Income)	2.21x	1.64x	2283.12x	0.75x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-0.18%	-0.77%	-	-
Return on Invested Capital (ROIC)	-0.14%	-3.24%	-	-
Debt / Equity	0.02x	0.26x	-	-
FCF Conversion	2.21x	1.64x	2283.12x	0.75x

Frequently Asked Questions

Growth & Financials

CERo Therapeutics Holdings, Inc. (CERO) reported $1.2M in revenue for fiscal year 2024.

CERo Therapeutics Holdings, Inc. (CERO) grew revenue by 0.0% over the past year. Growth has been modest.

CERo Therapeutics Holdings, Inc. (CERO) reported a net loss of $20.8M for fiscal year 2024.

Dividend & Returns

CERo Therapeutics Holdings, Inc. (CERO) had negative free cash flow of $8.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener